Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous Natural Killer and Natural Killer T Cell Immunotherapy
- Development stage
- Unknown
- Lead developer
- Envita Medical Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Envita Medical Center's Autologous Natural Killer (NK) and Natural Killer T (NKT) cell immunotherapy is an adoptive cell transfer biologic therapy designed to treat various treatment-refractory metastatic cancers. The process involves collecting a patient's own white blood cells via apheresis, followed by the ex vivo expansion and activation of NK and NKT cell populations using specific cytokines over a period of 3-4 weeks. Once activated, these cytotoxic immune cells are reinfused into the patient to target and eliminate malignant cells. This personalized immunotherapy platform, referred to by Envita as Autologous Adoptive Immunotherapy (AAIT), is currently being evaluated in Phase 1 clinical trials for indications including breast cancer, glioma, hepatocellular carcinoma, squamous cell lung cancer, pancreatic cancer, colon cancer, and prostate cancer.
- Other names
- NK and NKT Cell ImmunotherapyAutologous Adoptive ImmunotherapyAutologous Natural Killer / Natural Killer T Cell Immunotherapy
Beyond the preview
Go deeper on Autologous Natural Killer and Natural Killer T Cell Immunotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Autologous Natural Killer and Natural Killer T Cell Immunotherapy.